CClinicalTrials.gg
Status unknownNCT04565314Updated Feb 26, 2021

ELICIT 2.0: Pilot Study of the Effect of Maternal Protein Supplementation During Lactation on Childhood Growth

An interventional study of Plumpy'Mum in Growth Failure, Stunting and Malnutrition, sponsored by University of Virginia. Status unknown at 1 site in Tanzania. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by University of Virginia · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Haydom Global Health Research Center in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. The region around Haydom is agricultural (predominantly maize-based), is resource-poor and has a high degree of stunting among local infants-with 70% stunting by 18 months in the MAL-ED study and 50% in the ELICIT study (for Early Life Interventions for Childhood Growth and Development In Tanzania). While the causes of this stunting are multifactorial, a potential contributor is early-life nutritional deficiencies, including inadequate dietary protein.

One likely source of low protein delivery to infants is from low intake among area mothers during lactation, with potential effects on breast milk protein content and child weight gain. The current study is a pilot study assessing our study team's ability to successfully deliver protein-containing food products (a balanced-energy protein supplement) to lactating mother is in the area and assessing whether consumption of these food products improves childhood growth in the 1st year of life. This is a pilot study because of the potential difficulties in distributing these products on a large scale for daily consumption. As such, we aim to demonstrate an effective distribution network, a means of assessing adherence, and measuring endpoints while gathering knowledge regarding community acceptance. The current pilot project will evaluate the effectiveness of distribution and adherence on approximately 100 mother/child dyads. If effective, a future project could involve a large enough sample to be powered to detect reasonable changes in linear growth. .

So, while the current proposal is not adequately powered to prove a hypothesis, the hypothesis underlying the study design is that daily protein supplementation delivered as a balanced protein product (Plumpy'mum) to lactating mothers for 3 months during the period from 0-6 months post-natal life will result in an increase in infant length-for-age Z-score (LAZ) by end of treatment. LAZ will be compared to controls from prior studies in the area.

Read the detailed description

In severely under-resourced areas of the world, such as the Haydom area in Tanzania (TZ), poor nutrition continues contributes to worsened health-related outcomes including growth and cognitive development. Haydom Global Health Research Center at Haydom Lutheran Hospital in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. Through ongoing work in the area around Haydom in the MAL-ED and ELICIT studies, we have been attempting to improve outcomes for children in an area of severe poverty, where there is considerable malnutrition and potential sequelae:

  1. Growth deficits: Poor weight gain and linear growth failure in childhood are often seen as surrogates for overall health status; persistently poor growth has implications for future work potential and lower human capital. There was a high degree of stunting in the Haydom site of Tanzanian in the multi-country observational MAL-ED study, which found that the Haydom site had the highest prevalence of stunting among all the MAL-ED sites. This degree of stunting is likely multi-factorial, though one contributor is food availability, as rates of key factors such as birthweight vary significantly according to food availability. An interim analysis of data from our ongoing ELICIT study (for Early Life Interventions for Childhood

Developmental delays: Perhaps there is no more important outcome (with the exception of mortality) than the cognitive, social and emotional development of a population, with clear extensions to human capital, economic productivity and quality of life in communities. Indeed, many observational and interventional studies (including the current study) follow growth as an outcome because of its overall association with cognitive development. In MAL-ED assessments, TZ children had fewer words than seen among US children. The reasons for potential developmental delays are multifactorial, but again malnutrition may play an important role. Studies in other developing areas have demonstrated improved cognitive development following delivery of nutrition support.

Nutritional Causes of Poor Growth

While the causes of the stunting and developmental delays are multifactorial, a potential contributor is early-life nutritional deficiencies, including inadequate dietary protein. One likely source of low protein delivery to infants is from low intake among area mothers during lactation, with potential effects on breast milk protein content and child weight gain. Indeed, the first six months of life represents a critical phase of nutrition for the developing infant, in which all (or nearly all) nutrition is delivered through the mother's breast milk. However, it is not known whether protein supplementation during lactation in this setting would improve childhood growth and reduce stunting-or whether any improvements in growth would continue beyond the period of maternal supplementation.

Assessing the potential effect of mothers receiving protein supplementation-using a balanced energy protein supplement-on childhood growth and development would require an approach that incorporates an effective distribution network, a means of assessing adherence, and a thorough knowledge of community acceptance, as well as accurate measures of endpoints on a large enough sample to be powered to detect reasonable changes in linear growth. In order to assess the feasibility of this type of approach on a smaller scale (which could be later be expanded), the current pilot project will evaluate the effectiveness of distribution and adherence on approximately 100 mother/child dyads. If this experimental approach is feasible and shows promise, it is our hope to follow it with a larger study that offers more definitive evidence of efficacy.

02

Conditions studied

  • Growth Failure
  • Stunting
  • Malnutrition
  • Protein Malnutrition

Keywords

  • protein
  • breast feeding
  • eggs
  • Ready-to-eat food
  • infant
  • growth
  • Tanzania
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Maternal age >/= 18 years
  • Current pregnancy or infant \</= 3 months

Exclusion criteria

Exclusion Criteria:

  • Maternal inability to adhere to protocol
  • Multiple gestation
  • Significant birth defect
  • Maternal allergy to peanut, milk or soy
  • Lack of breast feeding at enrollment (and lack of intention to continue breast feeding at time of enrollment
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Plumpy'Mum

    Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area.

    Dietary Supplement: Plumpy'Mum

Interventions

  • Dietary supplementPlumpy'Mum

    Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.

05

What researchers measure

Primary outcomes

  1. Family perception of Plumpy'Mum

    Families will be queried about their impression of Plumpy'Mum

    Time frame: at 3 months after enrollment

Secondary outcomes

  1. Child weight-for-age Z-score (WAZ) after 3 months of Plumpy'Mum use

    Child weight for WHO Z-score after 3 months of Plumpy'Mum use compared to historical controls

    Time frame: 3 months

  2. Child head circumference-for-age Z-score (HCZ) after 3 months of Plumpy'Mum use

    Child head circumference for WHO Z-score after 3 months of Plumpy'Mum use compared to historical controls

    Time frame: 3 months

  3. Child mid-upper arm circumference-for-age Z-score (MUAC-Z) after 3 months of Plumpy'Mum use

    Child mid-upper arm circumference Z-score after 3 months of Plumpy'Mum use compared to historical controls

    Time frame: 3 months

  4. Child length-for-age Z-score (LAZ) after 3 months of Plumpy'Mum use

    Child length for WHO Z-score after 3 months of Plumpy'Mum use compared to historical controls

    Time frame: 3 months

  5. Adverse events

    Number of adverse events in intervention arm, compared to historical controls

    Time frame: 3 months

  6. Maternal weight at 3 months

    Maternal weight at 3 months compared to historical controls

    Time frame: 3 months

  7. Maternal mid-upper arm circumference-for-age Z-score (MUAC) at 3 months

    Maternal mid-upper arm circumference at 3 months compared to historical controls

    Time frame: 12 months

06

Study locations

1 site
  • Haydom Lutheran Hospital
    Mbulu, Manyara, Tanzania
07

References and documents

Individual participant data

Plan to share: Yes — We will assess platforms for sharing individual participant data following final data analysis.

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04565314
Lead sponsor
University of Virginia
Collaborators
Haydom Lutheran Hospital, Bill and Melinda Gates Foundation
Responsible party
Mark D. DeBoer, MD, MSc., MCR (Professor of Pediatrics, University of Virginia) — Principal investigator
First posted
Sep 25, 2020
Start date
Nov 12, 2019
Primary completion
Mar 31, 2022 (estimated)
Completion
Aug 1, 2022 (estimated)
Last update
Feb 26, 2021

Study contacts

Mark D DeBoer, MD, MSc, MCR
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion